Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B
Authors:
- Imanol Zubiete-FrancoIZImanol Zubiete-Franco
- Qingting HuQHQingting Hu
- Nicholas K TonksNTNicholas K Tonks
Preprint
Abstract
CDKL5-deficiency disorder or CDD, which results in intellectual disability, speech and motor deficits, and seizures that can start as early as six weeks after birth, is caused by de novo mutations in the CDKL5 gene. In early 2022, the FDA approved Ganaxolone (Commercial name: Ztalmy) for treatment of seizures in CDD patients 2 years and older. Ganaxolone has been reported to act as a GABAA receptor agonist that helps reduce neuronal excitability; however, based on its chemical structure we hypothesized that ganaxolone may also act as a PTP1B inhibitor. We observed that ganaxalone was able to inhibit PTP1B activity both in an in vitro assay of enzyme activity and in different cell models, in a comparable way to known inhibitors of PTP1B, including MSI-1436, which has a similar chemical structure. Additionally, inhibition of PTP1B in differentiating SH-SY5Y cells increased TRKB/BDNF signaling. This effect was prominent in CDKL5-KO cells, where inhibition of PTP1B brought TRKB levels and BDNF signaling to levels similar to those of wild-type cells and the observed signaling changes also coincided with restoration of cellular morphology. Finally, loss of CDKL5 function resulted in increased levels of PTP1B. Our results suggest that, like in Rett syndrome, targeting PTP1B may be a beneficial therapeutic strategy for CDD.Keywords
All Related Versions
- Published version: Journal of Biological Chemistry, 302 (7), 113178.
Funding Information
- NIH (R01CA53840)
- Cancer Center at Cold Spring Harbor Laboratory (CA45508)
- Dane G. Hansen Foundation
This publication has 70 references indexed in Scilit:
- Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based TherapyEpilepsy Research, 2025
- Ganaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency DisorderPediatric Drugs, 2025
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trialEuropean Journal of Paediatric Neurology, 2024
- Overexpression of forebrain PTP1B leads to synaptic and cognitive impairments in obesityBrain, Behavior, and Immunity, 2024
- Protein Tyrosine Phosphatases: Mighty oaks from little acorns growIUBMB Life, 2023
- Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disordersBiomedicine & Pharmacotherapy, 2022
- Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency DisorderNeurotherapeutics, 2022
- Inhibitory effects of glucagon-like peptide-1 receptor on epilepsyBiochemical and Biophysical Research Communications, 2019
- CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary FunctionCell Reports, 2018
- Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1Biological Psychiatry, 2016